A Long-Awaited Reversal

The American Cancer Society has substantially rewritten its prostate cancer screening guidance, abandoning years of caution in favor of routine prostate-specific antigen (PSA) testing for the large majority of American men. The new recommendations, released Thursday, mark one of the most consequential shifts in men's health policy in more than a decade and put the country's largest cancer advocacy organization squarely behind a test it once treated with deep skepticism.

Under the updated guideline, men at average risk should receive a PSA test every two years between the ages of 50 and 69. Men considered at elevated risk — because of race or family history — should begin earlier, at 45, and in most cases be tested annually.

Who Should Be Screened, and How Often

The guideline is built around a risk-stratified schedule rather than a single blanket rule, a structure that Ars Technica noted represents the most detailed set of recommendations the organization has ever issued on the subject.

  • Average-risk men: PSA testing every two years from age 50 through 69.
  • Black men: yearly testing beginning at age 45. Black men experience disproportionately higher rates of prostate cancer incidence and mortality.
  • Non-Black men with a close relative diagnosed before age 65, or with more than one relative diagnosed with prostate cancer: yearly testing beginning at 45.
  • Non-Black men with a single close relative diagnosed at age 65 or older: screening begins at 45, but on an every-two-years schedule.

The guideline focuses on men up to age 69; decisions for older men, and for those with limited life expectancy, remain a matter of individual discussion with a clinician. Medical trade outlets including Medical Xpress framed the update as a formal endorsement of regular PSA testing for both average- and high-risk men — a notable departure from the shared-decision-making language that had dominated prior guidance.

Why the Change

The ACS's previous position, aligned for years with the U.S. Preventive Services Task Force's 2012 decision to grade PSA screening a "D" recommendation, emphasized the harms of overdiagnosis: false positives, unnecessary biopsies, and the overtreatment of slow-growing tumors that would never have caused symptoms. That stance was later softened in 2018, when the task force moved to individualized decision-making for men aged 55 to 69.

The new guidance reflects a reassessment of that balance. Nearly 334,000 new prostate cancer cases are expected to be diagnosed in the United States this year, with more than 36,000 men projected to die of the disease, according to figures cited by News 12 Westchester. The network reported that cases are rising and that the increase is likely due in part to more men being screened — but also that many men are still not being screened early enough for the disease to be caught at its most treatable stage.

A Celebrity Voice and a Push on Symptoms

The guideline landed alongside a public-awareness push timed to September's Prostate Cancer Awareness Month. Super Bowl-winning coach Bruce Arians, who has publicly discussed his own experience with the disease, is fronting a campaign urging men to get tested.

"It will save your life." — Bruce Arians, urging men to get screened for prostate cancer

Consumer outlets took a different angle on the same story. NBC's TODAY focused on symptom awareness, publishing a physician's account of the four warning signs he monitors in himself — a framing that emphasizes what men should notice rather than the calendar of testing. Commonly cited red flags include changes in urinary frequency or flow, blood in urine or semen, erectile dysfunction, and persistent pain in the pelvis, back, or hips.

Aggregators including MSN carried the guideline news largely as a service-journalism item, distilling it into practical questions about when to call a doctor. The split in coverage illustrates how the same announcement functions differently depending on the audience: a policy milestone for specialist readers, a screening reminder for the general public.

What It Means in Practice

The practical effect is likely to be a measurable increase in testing volume, particularly among Black men and men with family histories who may have delayed screening during the years when the guidance was more equivocal. It also shifts the burden of initiating the conversation. Where earlier guidance placed the onus on patients and clinicians to weigh trade-offs case by case, the new document provides a default schedule.

Critics of expanded PSA screening are likely to argue that the harms have not disappeared: elevated PSA results frequently prompt biopsies that turn out to be benign, and active surveillance — now far more common than it was in 2012 — remains essential to avoiding treatment for tumors that pose little threat. Proponents counter that mortality from prostate cancer remains stubbornly high, that improved imaging and genomic testing have made the diagnostic pathway safer than it was when the skepticism took hold, and that the men most likely to die are those diagnosed late.

For now, the message from the ACS is unambiguous: for most men between 50 and 69, regular PSA testing is no longer an optional conversation. It is the recommendation.